These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
209 related articles for article (PubMed ID: 29939324)
1. Identification of genomic and molecular traits that present therapeutic vulnerability to HGF-targeted therapy in glioblastoma. Sa JK; Kim SH; Lee JK; Cho HJ; Shin YJ; Shin H; Koo H; Kim D; Lee M; Kang W; Hong SH; Kim JY; Park YW; Song SW; Lee SJ; Joo KM; Nam DH Neuro Oncol; 2019 Feb; 21(2):222-233. PubMed ID: 29939324 [TBL] [Abstract][Full Text] [Related]
2. Genomic profiling of a Hepatocyte growth factor-dependent signature for MET-targeted therapy in glioblastoma. Johnson J; Ascierto ML; Mittal S; Newsome D; Kang L; Briggs M; Tanner K; Marincola FM; Berens ME; Vande Woude GF; Xie Q J Transl Med; 2015 Sep; 13():306. PubMed ID: 26381735 [TBL] [Abstract][Full Text] [Related]
3. Preclinical development of a humanized neutralizing antibody targeting HGF. Kim H; Hong SH; Kim JY; Kim IC; Park YW; Lee SJ; Song SW; Kim JJ; Park G; Kim TM; Kim YH; Park JB; Chung J; Kim IH Exp Mol Med; 2017 Mar; 49(3):e309. PubMed ID: 28336956 [TBL] [Abstract][Full Text] [Related]
4. Reversion of human glioblastoma malignancy by U1 small nuclear RNA/ribozyme targeting of scatter factor/hepatocyte growth factor and c-met expression. Abounader R; Ranganathan S; Lal B; Fielding K; Book A; Dietz H; Burger P; Laterra J J Natl Cancer Inst; 1999 Sep; 91(18):1548-56. PubMed ID: 10491431 [TBL] [Abstract][Full Text] [Related]
5. YYB-101, a Humanized Antihepatocyte Growth Factor Monoclonal Antibody, Inhibits Ovarian Cancer Cell Motility and Proliferation. Kim HJ; Heo K Anticancer Res; 2021 Feb; 41(2):671-678. PubMed ID: 33517271 [TBL] [Abstract][Full Text] [Related]
6. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors. Burgess T; Coxon A; Meyer S; Sun J; Rex K; Tsuruda T; Chen Q; Ho SY; Li L; Kaufman S; McDorman K; Cattley RC; Sun J; Elliott G; Zhang K; Feng X; Jia XC; Green L; Radinsky R; Kendall R Cancer Res; 2006 Feb; 66(3):1721-9. PubMed ID: 16452232 [TBL] [Abstract][Full Text] [Related]
7. Interactions between PTEN and the c-Met pathway in glioblastoma and implications for therapy. Li Y; Guessous F; DiPierro C; Zhang Y; Mudrick T; Fuller L; Johnson E; Marcinkiewicz L; Engelhardt M; Kefas B; Schiff D; Kim J; Abounader R Mol Cancer Ther; 2009 Feb; 8(2):376-85. PubMed ID: 19190120 [TBL] [Abstract][Full Text] [Related]
8. Subtype-specific signaling pathways and genomic aberrations associated with prognosis of glioblastoma. Park AK; Kim P; Ballester LY; Esquenazi Y; Zhao Z Neuro Oncol; 2019 Jan; 21(1):59-70. PubMed ID: 30053126 [TBL] [Abstract][Full Text] [Related]
9. Paeoniflorin Inhibits Hepatocyte Growth Factor- (HGF-) Induced Migration and Invasion and Actin Rearrangement via Suppression of c-Met-Mediated RhoA/ROCK Signaling in Glioblastoma. Yu G; Wang Z; Zeng S; Liu S; Zhu C; Xu R; Liu RE Biomed Res Int; 2019; 2019():9053295. PubMed ID: 30886866 [TBL] [Abstract][Full Text] [Related]
10. miR-504 suppresses mesenchymal phenotype of glioblastoma by directly targeting the FZD7-mediated Wnt-β-catenin pathway. Liu Q; Guan Y; Li Z; Wang Y; Liu Y; Cui R; Wang Y J Exp Clin Cancer Res; 2019 Aug; 38(1):358. PubMed ID: 31419987 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of tumor growth in a mouse xenograft model by the humanized anti-HGF monoclonal antibody YYB-101 produced in a large-scale CHO cell culture. Song SW; Lee SJ; Kim CY; Song JK; Jung EJ; Choi YB; Min SW; Oh JW J Microbiol Biotechnol; 2013 Sep; 23(9):1327-38. PubMed ID: 23851271 [TBL] [Abstract][Full Text] [Related]
12. A novel rabbit anti-hepatocyte growth factor monoclonal neutralizing antibody inhibits tumor growth in prostate cancer cells and mouse xenografts. Yu Y; Chen Y; Ding G; Wang M; Wu H; Xu L; Rui X; Zhang Z Biochem Biophys Res Commun; 2015 Aug; 464(1):154-60. PubMed ID: 26093299 [TBL] [Abstract][Full Text] [Related]
13. Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models. Piao Y; Park SY; Henry V; Smith BD; Tiao N; Flynn DL; de Groot JF Neuro Oncol; 2016 Sep; 18(9):1230-41. PubMed ID: 26965451 [TBL] [Abstract][Full Text] [Related]
14. The HGF inhibitory peptide HGP-1 displays promising in vitro and in vivo efficacy for targeted cancer therapy. Chen L; Li C; Zhu Y Oncotarget; 2015 Oct; 6(30):30088-101. PubMed ID: 26254225 [TBL] [Abstract][Full Text] [Related]
15. MET Tyrosine Kinase Inhibition Enhances the Antitumor Efficacy of an HGF Antibody. Farrell PJ; Matuszkiewicz J; Balakrishna D; Pandya S; Hixon MS; Kamran R; Chu S; Lawson JD; Okada K; Hori A; Mizutani A; Iwata H; de Jong R; Hibner B; Vincent P Mol Cancer Ther; 2017 Jul; 16(7):1269-1278. PubMed ID: 28341789 [TBL] [Abstract][Full Text] [Related]
16. Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells. Stangeland B; Mughal AA; Grieg Z; Sandberg CJ; Joel M; Nygård S; Meling T; Murrell W; Vik Mo EO; Langmoen IA Oncotarget; 2015 Sep; 6(28):26192-215. PubMed ID: 26295306 [TBL] [Abstract][Full Text] [Related]
17. Aberrant Al-Ghabkari A; Huang B; Park M Cells; 2024 Jan; 13(3):. PubMed ID: 38334610 [TBL] [Abstract][Full Text] [Related]